Profile data is unavailable for this security.
About the company
Celularity Inc. is a regenerative and cellular medicine company. It is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs that target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Interfyl and Rebound products. Its platform is Celularity IMPACT (Immuno-Modulatory Placental-derived Allogeneic Cell Therapy).
- Revenue in USD (TTM)42.69m
- Net income in USD-112.83m
- Incorporated2018
- Employees120.00
- LocationCelularity Inc170 Park AveFLORHAM PARK 07932United StatesUSA
- Phone+1 (908) 768-2170
- Fax+1 (302) 636-5454
- Websitehttps://celularity.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mural Oncology PLC | 0.00 | -153.78m | 57.42m | 109.00 | -- | 0.3297 | -- | -- | -9.14 | -9.14 | 0.00 | 10.22 | 0.00 | -- | -- | 0.00 | -131.73 | -- | -168.84 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.29 | -- | -- | -- |
| enVVeno Medical Corp | 0.00 | -21.24m | 57.87m | 31.00 | -- | 1.22 | -- | -- | -1.33 | -1.33 | 0.00 | 2.70 | 0.00 | -- | -- | 0.00 | -54.12 | -58.43 | -57.23 | -62.76 | -- | -- | -- | -260,799.30 | -- | -- | 0.00 | -- | -- | -- | 4.67 | -- | 21.58 | -- |
| Champions Oncology Inc | 51.66m | -3.40m | 58.05m | 210.00 | -- | -- | -- | 1.12 | -0.2541 | -0.2541 | 3.78 | -0.0244 | 1.88 | -- | 5.75 | 245,976.20 | -12.39 | -10.00 | -44.43 | -23.00 | 44.27 | 46.58 | -6.58 | -6.04 | -- | -- | 333.00 | -- | -6.90 | 13.13 | -36.38 | -- | 0.0479 | -- |
| Atara Biotherapeutics Inc | 100.44m | -133.16m | 60.09m | 159.00 | -- | -- | -- | 0.5982 | -26.44 | -26.44 | 18.00 | -15.77 | 0.606 | 1.69 | 134.10 | 446,395.60 | -80.34 | -70.20 | -276.19 | -86.94 | 82.70 | -- | -132.58 | -1,559.33 | 0.4993 | -46.83 | -- | -- | -86.51 | -- | -20.95 | -- | -49.14 | -- |
| Bioqual Inc | -100.00bn | -100.00bn | 60.37m | 108.00 | -- | 1.63 | -- | -- | -- | -- | -- | 41.34 | -- | -- | -- | -- | -- | 8.14 | -- | 9.52 | -- | 19.36 | -- | 7.13 | -- | -- | 0.00 | 21.43 | -5.27 | 11.79 | -84.12 | -25.26 | 1.60 | 10.76 |
| Cue Biopharma Inc | 9.53m | -44.61m | 62.01m | 53.00 | -- | 2.44 | -- | 6.51 | -0.906 | -0.906 | 0.1925 | 0.4213 | 0.1677 | -- | 3.96 | 179,849.10 | -78.47 | -57.45 | -111.95 | -68.41 | -- | -- | -468.02 | -810.87 | -- | -- | 0.1726 | -- | 340.88 | 36.88 | 4.30 | -- | -- | -- |
| X4 Pharmaceuticals Inc | 1.12m | -16.76m | 62.08m | 93.00 | -- | 1.04 | -- | 55.28 | -0.0853 | -0.0853 | 0.0056 | 0.3538 | 0.0064 | -- | 1.53 | 12,075.27 | -9.54 | -61.53 | -11.29 | -69.20 | 55.92 | -- | -1,492.34 | -13,288.93 | 4.80 | -- | 0.5579 | -- | -- | -- | -4.93 | -- | 12.03 | -- |
| Immuneering Corp | 0.00 | -58.07m | 62.57m | 66.00 | -- | 1.14 | -- | -- | -1.97 | -1.97 | 0.00 | 1.86 | 0.00 | -- | -- | 0.00 | -63.66 | -- | -68.36 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -5.86 | -- | -- | -- |
| Celularity Inc | 42.69m | -112.83m | 62.66m | 120.00 | -- | 2.25 | -- | 1.47 | -5.77 | -5.77 | 2.14 | 1.27 | 0.2236 | 3.92 | 4.65 | 355,750.00 | -59.09 | -19.19 | -90.61 | -20.99 | 60.24 | -- | -264.30 | -454.79 | 0.2182 | -11.18 | 0.5958 | -- | 26.68 | -- | -1,483.14 | -- | -- | -- |
| RetinalGenix Technologies Inc | 0.00 | -4.04m | 62.99m | 0.00 | -- | -- | -- | -- | -0.2291 | -0.2291 | 0.00 | -0.101 | 0.00 | -- | -- | -- | -9,059.05 | -9,163.75 | -- | -- | -- | -- | -- | -- | -- | -1,050.46 | -- | -- | -- | -- | 46.58 | -- | -- | -- |
| Spero Therapeutics Inc | 106.46m | 3.51m | 64.32m | 46.00 | 19.54 | 0.9867 | 17.94 | 0.6042 | 0.0609 | 0.0609 | 1.97 | 1.21 | 0.8788 | -- | 3.78 | 2,314,239.00 | 2.90 | -35.52 | 4.19 | -41.75 | -- | -- | 3.30 | -124.40 | -- | -- | 0.00 | -- | 93.95 | 92.11 | 149.14 | -- | -- | -- |
| Allovir Inc | 0.00 | -100.20m | 65.86m | 112.00 | -- | 0.5433 | -- | -- | -0.8755 | -0.8755 | 0.00 | 1.05 | 0.00 | -- | -- | 0.00 | -54.04 | -52.85 | -59.58 | -57.72 | -- | -- | -- | -378,613.90 | -- | -- | 0.00 | -- | -- | -- | -12.87 | -- | -- | -- |
| Agenus Inc | 160.43m | -227.86m | 67.09m | 389.00 | -- | -- | -- | 0.4182 | -11.06 | -11.06 | 7.81 | -13.48 | 0.559 | -- | 259.38 | 412,408.80 | -81.56 | -55.02 | -663.00 | -115.31 | 99.61 | -- | -145.89 | -102.92 | -- | -0.7247 | -- | -- | 59.47 | 33.56 | -11.66 | -- | 22.58 | -- |
| Bioatla Inc | 11.00m | -81.82m | 67.20m | 65.00 | -- | 2.93 | -- | 6.11 | -1.70 | -1.70 | 0.2284 | 0.4751 | 0.103 | -- | -- | 169,230.80 | -76.61 | -48.72 | -103.22 | -57.35 | -- | -- | -743.79 | -6,651.71 | -- | -- | 0.00 | -- | -- | -- | -15.95 | -- | -37.01 | -- |
| CytomX Therapeutics Inc | 126.62m | 13.83m | 67.81m | 120.00 | 5.17 | -- | 4.33 | 0.5356 | 0.1675 | 0.1675 | 1.52 | -0.2998 | 0.7031 | -- | 43.88 | 1,055,142.00 | 7.68 | -21.53 | 29.38 | -32.32 | -- | -- | 10.92 | -100.38 | -- | -- | -- | -- | 90.38 | 11.21 | 99.43 | -- | -26.01 | -- |
Data as of Nov 22 2024. Currency figures normalised to Celularity Inc's reporting currency: US Dollar USD
11.21%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Starr Investment Holdings LLCas of 30 Apr 2024 | 1.53m | 7.02% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 497.82k | 2.29% |
| Geode Capital Management LLCas of 30 Sep 2024 | 137.47k | 0.63% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 101.18k | 0.46% |
| HB Wealth Management LLC (GA)as of 30 Sep 2024 | 35.84k | 0.17% |
| Cresset Asset Management LLCas of 30 Sep 2024 | 35.00k | 0.16% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2024 | 34.06k | 0.16% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 26.63k | 0.12% |
| Renaissance Technologies LLCas of 30 Sep 2024 | 23.38k | 0.11% |
| City National Rochdale LLCas of 30 Sep 2024 | 22.50k | 0.10% |
More ▼
Data from 30 Apr 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
